Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

BACKGROUND: Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). METHODS: This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in patients wi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Nephrol
Главные авторы: Grall, Maximilien, Daviet, Florence, Chiche, Noémie Jourde, Provot, François, Presne, Claire, Coindre, Jean-Philippe, Pouteil-Noble, Claire, Karras, Alexandre, Guerrot, Dominique, François, Arnaud, Benhamou, Ygal, Veyradier, Agnès, Frémeaux-Bacchi, Véronique, Coppo, Paul, Grangé, Steven
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2021
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8293501/
https://ncbi.nlm.nih.gov/pubmed/34284729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-021-02470-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы